UPDATE: Jefferies Reiterates Buy Rating, Lowers PT on Amarin Corporation plc on Continued ANCHOR Partnership Discussion

In a report published Friday, Jefferies analyst Thomas Wei reiterated a Buy rating on

, but lowered the price target from $24.00 to $20.00. In the report, Jefferies noted, “We remain focused on the FDA panel meeting in October for ANCHOR and the launch of ANCHOR in 1H14 as the key catalysts for AMRN shares. The company remains in negotiations for a pharma partnership for ANCHOR, but also discussed the merits of self-commercialization.” Amarin Corporation plc closed on Thursday at $5.31.